MarketPulse

Dupixent

11 articles
BenzingaBenzinga··Vandana Singh

Sanofi Beats Earnings as Dupixent Expansion Into Pediatric Urticaria Broadens Growth

Sanofi's Dupixent gains FDA approval for pediatric urticaria as Q1 earnings beat expectations with 30.8% drug growth at $12.31B sales.
SNYREGNchronic spontaneous urticariaFDA approval
GlobeNewswire Inc.GlobeNewswire Inc.··Sanofi And Regeneron

Dupixent Wins FDA Nod for Young Children With Chronic Urticaria, Expanding Market Reach

FDA approves Dupixent for children ages 2-11 with uncontrolled chronic spontaneous urticaria, marking first biologic treatment for this pediatric population.
SNYREGNchronic spontaneous urticariaFDA approval
GlobeNewswire Inc.GlobeNewswire Inc.··Sanofi And Regeneron

Sanofi and Regeneron Win FDA Nod for Dupixent in Young Children With Chronic Urticaria

FDA approves Dupixent for children ages 2-11 with chronic spontaneous urticaria, marking first biologic treatment for this pediatric population.
SNYREGNchronic spontaneous urticariaFDA approval
GlobeNewswire Inc.GlobeNewswire Inc.··Sanofi/Regeneron

Sanofi, Regeneron Win EU Approval for Dupixent in Pediatric Chronic Urticaria

Sanofi and Regeneron win EU approval for Dupixent as first targeted therapy for chronic urticaria in children ages 2-11, expanding the blockbuster drug's market reach.
SNYREGNDupixentdupilumab
GlobeNewswire Inc.GlobeNewswire Inc.··Sanofi And Regeneron

Sanofi, Regeneron Win EU Nod for Dupixent in Young Children with Chronic Urticaria

Dupixent gains European approval for treating moderate-to-severe chronic spontaneous urticaria in children ages 2-11, expanding the drug's pediatric portfolio.
SNYREGNchronic spontaneous urticariaDupixent
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Regeneron Stock Rally Masks Reality: Respectable Returns, Not Millionaire-Maker Gains

Regeneron's 35% recovery masks limited multimillionaire potential at $79B valuation, positioning shares for S&P-matching returns rather than exceptional gains.
REGNbiotechclinical trials
GlobeNewswire Inc.GlobeNewswire Inc.··Sanofi And Regeneron

Dupixent Wins Japan Approval for Rare Autoimmune Disorder, Expanding Sanofi-Regeneron Pipeline

Sanofi and Regeneron's Dupixent secured Japanese regulatory approval for bullous pemphigoid, marking the drug's seventh indication in Japan with superior remission rates versus placebo.
SNYREGNclinical trialDupixent
GlobeNewswire Inc.GlobeNewswire Inc.··Sanofi And Regeneron

Sanofi and Regeneron's Dupixent Wins Japan Approval for Rare Skin Disorder

Dupixent receives Japanese marketing authorization for bullous pemphigoid, becoming the first targeted treatment. Study showed 18% remission rate versus 4% for placebo.
SNYREGNmonoclonal antibodyclinical trial
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Regeneron's Pipeline Depth and Dupixent Dominance Set Stage for Decade of Growth

Regeneron's Dupixent dominance and deep pipeline across weight management, oncology, and rare diseases position the company for sustained growth through the mid-2030s.
REGNbiotechpatent cliff
BenzingaBenzinga··Vandana Singh

FDA Expands Dupixent Approval to Allergic Fungal Rhinosinusitis

FDA approves Dupixent for allergic fungal rhinosinusitis in patients six and older, marking the drug's ninth indication for treating type 2 inflammatory conditions.
SNYREGNFDA approvalPhase 3 trial
BenzingaBenzinga··Vandana Singh

Sanofi Shares Slide as Hudson Steps Down; Garijo to Lead Post-AGM

Sanofi CEO Paul Hudson steps down February 17; Belén Garijo takes over post-AGM. Stock fell 4.5% on leadership transition announcement amid vaccine sales decline concerns.
SNYREGNstock declineCEO transition